Joachim Rom

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

Shannon N. Westin, Kathleen N. Moore, Hye Sook Chon et al. · Journal of Clinical Oncology · 2023 · 331 citations · Full text

Medicine, Oncology, Pharmacology +12

Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome

Yingzi Ge, Christoph Domschke, Natalija Stoiber et al. · Cancer Immunology Immunotherapy · 2011 · 227 citations · Full text

Medicine, Immunology, Oncology +17

The cancer-associated microprotein CASIMO1 controls cell proliferation and interacts with squalene epoxidase modulating lipid droplet formation

Maria Polycarpou‐Schwarz, Matthias Groß, Pieter Mestdagh et al. · Oncogene · 2018 · 178 citations

Medicine, Molecular Biology, Oncology +16

Genome‐wide methylation screen in low‐grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis

Marta Faryna, Carolin Konermann, Sebastian Aulmann et al. · The FASEB Journal · 2012 · 89 citations · Full text

Medicine, Molecular Biology, Oncology +17